Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?

Area of Science:

• Endocrinology
• Oncology
• Pathology

Background:

• The BRAF (V600E) mutation is infrequently observed in Hashimoto thyroiditis (HT).
• Factors influencing HT development remain largely unknown.
• This study investigates HT's clinicopathological features in papillary thyroid carcinoma (PTC) patients.

Purpose of the Study:

• To determine if PTC patients with HT exhibit more aggressive characteristics.
• To analyze the relationship between HT and clinicopathological features in PTC.

Main Methods:

• Retrospective review of 2464 PTC patients who underwent thyroidectomy (Oct 2008 - Aug 2012).
• BRAF (V600E) mutation analysis using DNA from surgical specimens.
• Investigation of clinical and pathological characteristics.

Main Results:

• HT was diagnosed in 23.2% of patients; 72.1% of these had the BRAF (V600E) mutation.
• HT was associated with low stage and female predominance, but not significantly with BRAF (V600E) mutation or extrathyroidal extensions.
• HT showed an inverse relationship with recurrence (OR 0.297) and was linked to lower BRAF (V600E) mutation probability in both genders.

Conclusions:

• HT in PTC patients correlates with a lower probability of BRAF (V600E) mutations.
• HT is associated with less aggressive clinical features and reduced recurrence risk.
• Concurrent HT may predict a better prognosis for PTC patients compared to PTC alone.